What Is a GLP-1?

1. What Does GLP-1 Mean?

GLP-1 stands for glucagon-like peptide-1. NCBI MeSH describes it as a peptide derived from proglucagon and mainly produced by intestinal L cells; the same entry notes effects on glucose-dependent insulin release, glucagon release, gastric emptying, blood glucose, and food intake.

In everyday search results, however, "GLP-1" often means GLP-1 receptor agonist medications such as semaglutide or the dual GIP/GLP-1 receptor agonist tirzepatide. That shorthand is common, but it can blur the difference between a natural hormone and a drug product with specific labeling.

2. What Are GLP-1 Receptor Agonists?

NCBI Bookshelf describes GLP-1 receptor agonists as a medication class used for type 2 diabetes and, in some cases, obesity. Its mechanism section describes incretin-related effects including insulin secretion after oral glucose load, delayed gastric emptying, and reduced glucagon production when blood sugar is high.

That mechanism summary is not a personal treatment recommendation. It is background for understanding why the category appears in diabetes, obesity, cardiovascular-risk, and metabolic-health discussions. Any real product has its own label, route, duration, warnings, contraindications, and prescribing context.

Peptide Tracker uses this distinction in its content and interface. A record can say semaglutide, tirzepatide, Mounjaro, Zepbound, Wegovy, Ozempic, or another user-entered item. The app records what the user enters; it does not infer that similar names mean the same product.

3. Why Is Everyone Searching GLP-1?

KFF reported in May 2024 that about one in eight U.S. adults had ever taken a GLP-1 agonist, including 6% who were currently taking one. In that poll, 62% of people who had taken GLP-1 drugs said they used them at least partly for a chronic condition such as diabetes or heart disease.

Search demand follows real-life complexity. People look up GLP-1 terms because they are trying to understand product names, timing, missed logs, dose units, inventory, side effects, costs, and clinician conversations. A tracker is useful when it makes the record cleaner without pretending to resolve medical judgment.

4. Why Do GLP-1 Records Mention Half-Life?

Half-life helps explain timing models, not individual blood levels. DailyMed lists semaglutide's Wegovy elimination half-life as approximately 1 week and says semaglutide can remain in circulation for about 5 to 7 weeks after the last labeled Wegovy dose.

That is why a half-life chart may show overlap between logged entries. The chart is math based on a reference value. It is not a blood test, a symptom explanation, or dosing advice.

Peptide Tracker's half-life visualizer and concentration curves are built around this boundary. The app can plot user-entered dose history against a reference half-life, while the peptide half-life tracking guide explains the formula and limits in more detail.

5. What Can a GLP-1 Tracker Record?

A GLP-1 tracker can make the record readable: date, time, amount, unit, product, route or method note, injection site if relevant, reminder status, inventory context, symptoms or side-effect notes, progress metrics, bloodwork entries, and exports.

Peptide Tracker supports dose logs, schedules, injection-site history, side-effect records, inventory, BAC water records, half-life visualization, progress photos, Apple Health imports, bloodwork logs, and PDF/CSV/TXT exports. It is designed as a private recordkeeping tool, not a medical device or prescribing system.

6. Sources